Privia Health Group, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
PRVA$24.37-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| For the Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net income | $29,726 | $17,044 | $21,028 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation | 739 | 1,104 | 1,174 |
| Amortization of intangibles | 9,168 | 6,164 | 5,359 |
| Stock-based compensation | 71,068 | 56,680 | 37,098 |
| Deferred income taxes | 10,871 | 8,817 | 7,465 |
| Changes in asset and liabilities: | |||
| Accounts receivable, net | (36,668) | (19,824) | (96,877) |
| Prepaid expenses and other current assets | (1,599) | (8,970) | (6,159) |
| Other non-current assets and right-of-use assets | (326) | (1,721) | (2,418) |
| Accounts payable and accrued expenses | 14,824 | 19,905 | 4,994 |
| Provider liability | 65,629 | 32,942 | 113,367 |
| Operating lease liabilities | (2,459) | (2,699) | (3,214) |
| Other long-term liabilities | 2,431 | (160) | (1,032) |
| Net cash provided by operating activities | 163,404 | 109,282 | 80,785 |
| Cash flows from investing activities | |||
| Acquisitions, net of cash acquired | (180,370) | (6,957) | (42,858) |
| Other | (1,200) | (5,021) | (113) |
| Net cash used in investing activities | (181,570) | (11,978) | (42,971) |
| Cash flows from financing activities | |||
| Repurchase of non-controlling interest | — | — | (5,694) |
| Proceeds from non-controlling interest | — | 1,653 | 659 |
| Distribution to non-controlling interest | (1,345) | — | — |
| Proceeds from exercised stock options | 8,047 | 2,681 | 8,740 |
| Net cash provided by financing activities | 6,702 | 4,334 | 3,705 |
| Net (decrease) increase in cash and cash equivalents | (11,464) | 101,638 | 41,519 |
| Cash and cash equivalents at beginning of period | 491,149 | 389,511 | 347,992 |
| Cash and cash equivalents at end of period | $479,685 | $491,149 | $389,511 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | $251 | $285 | $40 |
| Income taxes paid, net of refunds | $6,639 | $3,755 | $1,040 |
| Supplemental disclosure of non-cash operating activities: | |||
| Leases liabilities obtained in exchange for right-of-use assets | $6,400 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.